Delivery technologies can improve the therapeutic window for existing drugs, providing patent protection and cost justification.  They might even make your difficult-to-deliver new chemical entity viable. It's no wonder that drug delivery technologies are of interest to both large pharmaceutical companies and to the growing crop of specialty pharmaceutical companies.

Learn what local drug delivery companies can do for your drug.  Drug delivery systems have expanded dosing beyond traditional pills to alternate administration routes, including transdermal, pulmonary, intravaginal, and others.  In addition, nanotechnology and molecular engineering offer the opportunity to deliver drugs safely and effectively to targeted sites.

This session will highlight some exciting regional developments in drug delivery technologies and partnering opportunities.  It will provide an overview of:

• The advances in drug delivery technologies
• Progress in the delivery of peptide drugs
• Life cycle management through innovative oral delivery
• New biomaterials for clinical use

Moderator:

• Gwilym Attwell, principal, Fish & Richardson P.C.

Panelists:

• James Gilligan, Ph.D., MSIB, vice president for product development, Unigene Laboratories, Inc.
• Troy Harmon, vice president, business development, Eurand ( Presentation)
• Joachim Kohn, Ph.D., professor of Chemistry & Chemical Biology, Rutgers, the State University of New Jersey
• Shawn Patrick O'Brien, president & CEO, Profectus BioSciences Inc. ( Presentation)

Is it a drug?  Is it a device?  Or is it both?  This might be a case where the whole is greater than the sum of its parts.  From a scientific perspective, learn how new device technologies can:

• Improve drugs and how drugs can also enhance devices, making each more effective
• Lower the dose of drugs while reducing their toxicity
• Have their effectiveness increased through the use of drugs

This session will address the emerging drug-device field and provide insights into the future of combination products.  The panelists will also examine regulatory issues for developing combination products and the potential market opportunity for these products. 

Moderator:

• Anand Gumaste, president & CEO, MicroDose Technologies, Inc.

Panelists:

• David Bergstrom, Ph.D., senior vice president & COO, NovaDel Pharma, Inc. ( Presentation)
• Janice Hogan, managing partner, Hogan & Hartson LLP ( Presentation)
• Scott Siegel, Ph.D., vice president of corporate development, RedPoint Bio Corporation
  ( Presentation)
• Philip Smith, partner, SR One

These are exciting times in the medical device world.  Devices are getting "smarter" and improving the quality of life for patients.  Advances in telemetry, for example, will enable devices to communicate remotely to doctors located miles away, eliminating expensive hospital stays, while implants for eyes and other body parts may reverse crippling disabilities.  Future devices will combine engineering and biological approaches to replace joints and tissues, enabling patients with previously untreatable conditions to be made whole again.

This session will focus on leading-edge device technologies, emphasizing those being developed by local companies.  Learn what's here now and what might become a part of you (literally) in the future.

While looking into the future, the panelists will also address the regulatory pathway and issues affecting reimbursement for current and future medical devices. 

Moderator:

• Dennis Willson, president & CEO, Cytokine PharmaSciences

Panelists:

• Simon Archibald, Ph.D., CSO, Integra LifeSciences Corporation
• David Fischell, Ph.D., CEO, Angel Medical Systems, Inc.
• Ray Krauss, CEO, GlucoLight Corporation ( Presentation)
• Jeffrey Marx, Ph.D., vice president of corporate development, Orthovita, Inc.